Literature DB >> 2690330

Omeprazole: pharmacokinetics and metabolism in man.

C Cederberg1, T Andersson, I Skånberg.   

Abstract

Omeprazole is acid labile and, therefore, has to be protected from exposure to the acidic gastric juice when given orally. Following a single oral dose of buffered suspension, omeprazole is rapidly absorbed with peak plasma concentrations within 0.5 hours. The volume of distribution is 0.3 litres/kg corresponding to the volume of extracellular water. In contrast to the long duration of antisecretory action, omeprazole is rapidly eliminated from plasma. The half-life is less than 1 hour, and omeprazole is almost entirely cleared from plasma within 3-4 hours. Omeprazole is completely metabolized in the liver. The two major plasma metabolites are the sulphone and hydroxyomeprazole, neither of which contributes to the antisecretory activity. About 80% of a given dose is excreted in the urine, and the remainder via the bile. The absorption of the coated granule formulation dispensed in hard gelatine capsules is slower, with peak concentrations 1-3 hours after dose. Bioavailability after a single dose is 35% and increases during repeated once-daily dosing to 60%. Omeprazole can potentially interact with the hepatic microsomal cytochrome P-450 enzymes. Studies show that the clearance of both diazepam and phenytoin are decreased and their terminal half-lives are increased during concomitant omeprazole treatment, both interactions being attributable to inhibition of hepatic metabolism. No interaction with propranolol or theophylline has been noted.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2690330     DOI: 10.3109/00365528909091241

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  23 in total

1.  Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study.

Authors:  Laurian Vlase; Maria Neag; Adina Popa; Dana Muntean; Sorin E Leucuta
Journal:  Curr Ther Res Clin Exp       Date:  2010-12

2.  Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.

Authors:  Eileen B Lawson; Jerry C Wu; R Michael Baldwin; Magnus Ingelman-Sundberg; Staffan Rosenborg; Dong-Seok Yim; Ophelia Q P Yin; Edmund V Capparelli; Joseph D Ma
Journal:  Eur J Clin Pharmacol       Date:  2011-10-19       Impact factor: 2.953

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 4.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

5.  Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics.

Authors:  H Stuht; H Lode; P Koeppe; K L Rost; T Schaberg
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

6.  Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects.

Authors:  S Teyssen; S T Chari; J Scheid; M V Singer
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

7.  Individual and group dose-responses to intravenous omeprazole in the first 24 h: pH-feedback-controlled and fixed-dose infusions.

Authors:  C H Wilder-Smith; H U Bettschen; H S Merki
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

8.  Omeprazole induces gastric permeability to digoxin.

Authors:  M Gabello; M C Valenzano; M Barr; P Zurbach; J M Mullin
Journal:  Dig Dis Sci       Date:  2009-06-10       Impact factor: 3.199

Review 9.  Prescribing policy for antiulcer treatment in the elderly.

Authors:  G Bianchi Porro; M Lazzaroni
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

Review 10.  Omeprazole drug interaction studies.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.